{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T02:48:18Z","timestamp":1776912498943,"version":"3.51.2"},"reference-count":32,"publisher":"Oxford University Press (OUP)","issue":"13","license":[{"start":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T00:00:00Z","timestamp":1646179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Purpose<\/jats:title>\n                  <jats:p>Prolonged duration of intravenous (IV) vasopressor dependence in critically ill adult patients with vasodilatory shock results in increased length of stay in both the intensive care unit (ICU) and hospital, translating to higher risk of infection, delirium, immobility, and cost. Acceleration of vasopressor liberation can aid in reducing these risks. Midodrine is an oral \u03b1\u200a1-adrenergic receptor agonist that offers a potential means of liberating patients from IV vasopressor therapy. This clinical review summarizes primary literature and proposes a clinical application for midodrine in the recovery phase of vasodilatory shock.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Summary<\/jats:title>\n                  <jats:p>Five studies with a total of over 1,000 patients conducted between 2011 and 2021 were identified. In observational studies, midodrine administration was demonstrated to lead to faster time to liberation from IV vasopressor therapy and shorter ICU length of stay in patients recovering from vasodilatory shock. These findings were not replicated in a prospective, multicenter, randomized controlled trial. In this review, literature evaluating midodrine use for IV vasopressor liberation is summarized and study limitations are discussed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>On the basis of this review of current literature, recommendations are provided on selecting appropriate candidates for adjunctive midodrine in the recovery phase of vasodilatory shock and considerations are discussed for safely and effectively initiating, titrating, and discontinuing therapy.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ajhp\/zxac069","type":"journal-article","created":{"date-parts":[[2022,3,2]],"date-time":"2022-03-02T22:52:31Z","timestamp":1646261551000},"page":"1047-1055","source":"Crossref","is-referenced-by-count":6,"title":["Putting midodrine on the MAP: An approach to liberation from intravenous vasopressors in vasodilatory shock"],"prefix":"10.1093","volume":"79","author":[{"given":"Susan E","family":"Smith","sequence":"first","affiliation":[{"name":"Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy , Athens, GA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas A","family":"Peters","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Indiana University Health , Indianapolis, IN , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren M","family":"Floris","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Atrium Health Navicent Medical Center , Macon, GA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua M","family":"Patterson","sequence":"additional","affiliation":[{"name":"Roberta Drugs , Roberta, GA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W Anthony","family":"Hawkins","sequence":"additional","affiliation":[{"name":"Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy , Athens, GA, USA"},{"name":"Department of Pharmacology and Toxicology, Medical College of Georgia at Augusta University , Albany, GA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2022,3,2]]},"reference":[{"issue":"9","key":"2022062308215066300_CIT0001","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1056\/NEJMoa0907118","article-title":"Comparison of dopamine and norepinephrine in the treatment of shock","volume":"362","author":"De Backer","year":"2010","journal-title":"N Engl J Med."},{"issue":"18","key":"2022062308215066300_CIT0002","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMra1208943","article-title":"Circulatory shock","volume":"369","author":"Vincent","year":"2013","journal-title":"N Engl J Med."},{"issue":"2","key":"2022062308215066300_CIT0003","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.chest.2017.12.021","article-title":"Management of refractory vasodilatory shock","volume":"154","author":"Jentzer","year":"2018","journal-title":"Chest."},{"issue":"5","key":"2022062308215066300_CIT0004","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1378\/chest.122.5.1784","article-title":"Adrenal insufficiency in the critically ill: a new look at an old problem","volume":"122","author":"Marik","year":"2002","journal-title":"Chest."},{"issue":"6","key":"2022062308215066300_CIT0005","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1152\/ajplegacy.1975.229.6.1649","article-title":"Renovascular resistance and noradrenaline","volume":"229","author":"Bomzon","year":"1975","journal-title":"Am J Physiol."},{"issue":"9","key":"2022062308215066300_CIT0006","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa067373","article-title":"Vasopressin versus norepinephrine infusion in patients with septic shock","volume":"358","author":"Russell","year":"2008","journal-title":"N Engl J Med."},{"issue":"12","key":"2022062308215066300_CIT0007","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1513\/AnnalsATS.201504-187OC","article-title":"Volume overload: prevalence, risk factors, and functional outcome in survivors of septic shock","volume":"12","author":"Mitchell","year":"2015","journal-title":"Ann Am Thorac Soc."},{"key":"2022062308215066300_CIT0008","doi-asserted-by":"crossref","first-page":"2050312120979464","DOI":"10.1177\/2050312120979464","article-title":"Association of hidden fluid administration with development of fluid overload reveals opportunities for targeted fluid minimization","volume":"8","author":"Branan","year":"2020","journal-title":"SAGE Open Med."},{"key":"2022062308215066300_CIT0009","article-title":"Hidden fluids in plain sight: identifying intravenous medication classes as contributors to intensive care unit fluid intake","author":"Gamble","year":"2021","journal-title":"Hosp Pharm."},{"issue":"8","key":"2022062308215066300_CIT0010","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1097\/CCM.0000000000003191","article-title":"Insidious harm of medication diluents as a contributor to cumulative volume and hyperchloremia: a prospective, open-label, sequential period pilot study","volume":"46","author":"Magee","year":"2018","journal-title":"Crit Care Med."},{"issue":"13","key":"2022062308215066300_CIT0011","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1056\/NEJMoa1500964","article-title":"Intravascular complications of central venous catheterization by insertion site","volume":"373","author":"Parienti","year":"2015","journal-title":"N Engl J Med."},{"issue":"3","key":"2022062308215066300_CIT0012","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4103\/2229-5151.164940","article-title":"Central line complications","volume":"5","author":"Kornbau","year":"2015","journal-title":"Int J Crit Illn Inj Sci."},{"issue":"5","key":"2022062308215066300_CIT0013","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jcrc.2013.05.021","article-title":"Oral midodrine treatment accelerates the liberation of intensive care unit patients from intravenous vasopressor infusions","volume":"28","author":"Levine","year":"2013","journal-title":"J Crit Care."},{"issue":"5","key":"2022062308215066300_CIT0014","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2165\/00003495-198938050-00004","article-title":"Midodrine. A review of its pharmacological properties and therapeutic use in orthostatic hypotension and secondary hypotensive disorders","volume":"38","author":"McTavish","year":"1989","journal-title":"Drugs."},{"key":"2022062308215066300_CIT0015","volume-title":"ProAmatine","year":"2017"},{"issue":"2","key":"2022062308215066300_CIT0016","first-page":"211","article-title":"Infectious toxic hypotension\u2014effect and dosage of midodrine","volume":"14","author":"Weippl","year":"1979","journal-title":"Padiatr Padol."},{"issue":"5","key":"2022062308215066300_CIT0017","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/clpt.1986.101","article-title":"Pharmacodynamics of midodrine, an antihypotensive agent","volume":"39","author":"Zachariah","year":"1986","journal-title":"Clin Pharmacol Ther."},{"issue":"5","key":"2022062308215066300_CIT0018","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.jcrc.2013.05.021","article-title":"Oral midodrine treatment accelerates the liberation of intensive care unit patients from intravenous vasopressor infusions","volume":"28","author":"Levine","year":"2013","journal-title":"J Crit Care."},{"issue":"6","key":"2022062308215066300_CIT0019","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.chest.2016.02.657","article-title":"Feasibility, utility, and safety of midodrine during recovery phase from septic shock","volume":"149","author":"Whitson","year":"2016","journal-title":"Chest."},{"issue":"3","key":"2022062308215066300_CIT0020","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/jcpt.12375","article-title":"Midodrine for the weaning of vasopressor infusions","volume":"41","author":"Poveromo","year":"2016","journal-title":"J Clin Pharm Ther."},{"issue":"7","key":"2022062308215066300_CIT0021","doi-asserted-by":"crossref","first-page":"e628","DOI":"10.1097\/CCM.0000000000003121","article-title":"Trends in use of midodrine in the ICU: a single-center retrospective case series","volume":"46","author":"Rizvi","year":"2018","journal-title":"Crit Care Med."},{"issue":"10","key":"2022062308215066300_CIT0022","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1007\/s00134-020-06216-x","article-title":"Effect of midodrine versus placebo on time to vasopressor discontinuation in patients with persistent hypotension in the intensive care unit (MIDAS): an international randomised clinical trial","volume":"46","author":"Santer","year":"2020","journal-title":"Intensive Care Med."},{"issue":"4","key":"2022062308215066300_CIT0023","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.chest.2016.07.039","article-title":"Using the proper analytical tools when evaluating the role of midodrine in resolving septic shock","volume":"150","author":"Sagar","year":"2016","journal-title":"Chest."},{"issue":"4","key":"2022062308215066300_CIT0024","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.chest.2016.08.1437","article-title":"Response","volume":"150","author":"Whitson","year":"2016","journal-title":"Chest."},{"issue":"6","key":"2022062308215066300_CIT0025","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1016\/j.chest.2016.03.054","article-title":"Considerations on midodrine use in resolving septic shock","volume":"149","author":"Hammond","year":"2016","journal-title":"Chest."},{"issue":"1","key":"2022062308215066300_CIT0026","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12871-017-0339-x","article-title":"Midodrine as adjunctive support for treatment of refractory hypotension in the intensive care unit: a multicenter, randomized, placebo controlled trial (The MIDAS trial)","volume":"17","author":"Anstey","year":"2017","journal-title":"BMC Anesthesiol."},{"issue":"3","key":"2022062308215066300_CIT0027","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1378\/chest.12-1106","article-title":"Survival after shock requiring high-dose vasopressor therapy","volume":"143","author":"Brown","year":"2013","journal-title":"Chest."},{"issue":"12","key":"2022062308215066300_CIT0028","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1097\/CCM.0000000000002737","article-title":"Guidelines for the diagnosis and management of critical illness-related corticosteroid insufficiency (CIRCI) in critically ill patients (part I): Society of Critical Care Medicine (SCCM) and European Society of Intensive Care Medicine (ESICM) 2017","volume":"45","author":"Annane","year":"2017","journal-title":"Crit Care Med."},{"issue":"7","key":"2022062308215066300_CIT0029","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1111\/jgs.12329","article-title":"Inappropriate medication prescriptions in elderly adults surviving an intensive care unit hospitalization","volume":"61","author":"Morandi","year":"2013","journal-title":"J Am Geriatr Soc."},{"issue":"2","key":"2022062308215066300_CIT0030","first-page":"147","article-title":"Inappropriate continuation of stress ulcer prophylaxis beyond the intensive care setting","volume":"15","author":"Farley","year":"2013","journal-title":"Crit Care Resusc."},{"key":"2022062308215066300_CIT0031","doi-asserted-by":"crossref","first-page":"S133","DOI":"10.2146\/ajhp150474","article-title":"Hospital delirium treatment: continuation of antipsychotic therapy from the intensive care unit to discharge","volume":"72","author":"Flurie","year":"2015","journal-title":"Am J Health-Syst Pharm."},{"issue":"8","key":"2022062308215066300_CIT0032","doi-asserted-by":"crossref","first-page":"e648","DOI":"10.1097\/CCM.0000000000003814","article-title":"Continuation of newly initiated midodrine therapy after intensive care and hospital discharge: a single-center retrospective study","volume":"47","author":"Rizvi","year":"2019","journal-title":"Crit Care Med."}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajhp\/advance-article-pdf\/doi\/10.1093\/ajhp\/zxac069\/42955491\/zxac069.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/79\/13\/1047\/44156513\/zxac069.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajhp\/article-pdf\/79\/13\/1047\/44156513\/zxac069.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T08:25:30Z","timestamp":1655972730000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/79\/13\/1047\/6541336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,2]]},"references-count":32,"journal-issue":{"issue":"13","published-online":{"date-parts":[[2022,3,2]]},"published-print":{"date-parts":[[2022,6,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ajhp\/zxac069","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,7,1]]},"published":{"date-parts":[[2022,3,2]]}}}